We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Takeda Pharmaceutical Co Ltd | LSE:0RN3 | London | Ordinary Share | JP3463000004 | TAKEDA PHARMACEUTICAL ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 49.35 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.05T | 317.02B | 200.3525 | 0.14 | 45.02B |
TIDM48QN TIDM0RN3
RNS Number : 7853M
Morgan Stanley & Co. Int'l plc
10 January 2019
AMENDMENT Section (2a)
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION (a) Name of exempt principal trader: Morgan Stanley & Co. International plc (b) Name of offeror/offeree in relation to whose relevant securities this Takeda Pharmaceutical Company Limited form relates: Use a separate form for each offeror/offeree --------------------------------------- (c) Name of the party to the offer with which exempt principal trader is Shire plc connected: --------------------------------------- (d) Date dealing undertaken: 07 JANUARY 2019 --------------------------------------- (e) In addition to the company in 1(b) above, is the exempt principal trader Yes - Shire plc making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state "N/A" --------------------------------------- 2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales Class of Purchases/ Total number Highest price Lowest price relevant sales of securities per unit paid/received per unit paid/received security Ordinary PURCHASES 509,317 4,074.0000 3,908.0000 JPY JPY ----------- --------------- ------------------------ ------------------------ Ordinary SALES 541,717 4,074.0000 3,923.0000 JPY JPY ----------- --------------- ------------------------ ------------------------ Ordinary PURCHASES 49,600 36.8971 USD 36.7058 USD ----------- --------------- ------------------------ ------------------------ (b) Cash-settled derivative transactions Class of Product description Nature of dealing Number of reference Price per relevant e.g. CFD e.g. opening/closing securities unit security a long/short position, increasing/reducing a long/short position N/A N/A N/A N/A N/A -------------------- ------------------------ -------------------- ---------- (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of Product Writing, Number Exercise Type e.g. Expiry Option relevant description purchasing, of securities price per American, date money paid/ security e.g. call selling, to which unit European received option varying option etc. per unit etc. relates N/A N/A N/A N/A N/A N/A N/A N/A ------------- ------------- --------------- ----------- ----------- ------- ------------- (ii) Exercise Class of Product description Exercising/ Number of securities Exercise price relevant e.g. call option exercised per unit security against N/A N/A N/A N/A N/A -------------------- ------------ --------------------- --------------- (d) Other dealings (including subscribing for new securities) Class of relevant Nature of dealing Details Price per unit security e.g. subscription, (if applicable) conversion N/A N/A N/A N/A -------------------- -------- ----------------- 3. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" NONE (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" NONE Date of disclosure: 10 JANUARY 2019 Contact name: Craig Horsley ------------------ Telephone number: +44(141) 245 7736 ------------------
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
FERCKKDNNBKDFDD
(END) Dow Jones Newswires
January 10, 2019 08:40 ET (13:40 GMT)
1 Year Takeda Pharmaceutical Chart |
1 Month Takeda Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions